{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Atiprimod",
  "nciThesaurus": {
    "casRegistry": "123018-47-3",
    "chebiId": "",
    "chemicalFormula": "C22H44N2",
    "definition": "An orally bioavailable small molecule belonging to the azaspirane class of cationic amphiphilic agents with anti-inflammatory, antineoplastic, and antiangiogenic properties. Atiprimod inhibits the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.",
    "fdaUniiCode": "MG7D3QD743",
    "identifier": "C52184",
    "preferredName": "Atiprimod",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1742",
      "C2189"
    ],
    "synonyms": [
      "ATIPRIMOD",
      "Atiprimod",
      "Azaspirane SK&F106615",
      "N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine",
      "SK&F106615",
      "atiprimod",
      "azaspirane"
    ]
  }
}